Lasmecabtagene timgedleucel

N/A

Report date: 2025/12/25 15:59:43

Base Information

Drug NameLasmecabtagene timgedleucel

Drug Alias NameT-cell adoptive immunotherapy (Cellectis)UCART-22

ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Allogeneic

Mechanisms of ActionImmunostimulantsCD22 modulatorsT lymphocyte replacements

TargetsCD22

Therapy Area/IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesFrance

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesCellectis Sa

China Registration ClassN/A

Develop Information

Active CompaniesCellectis Sa

Inactive CompaniesN/A

Active IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A